Spondyloarthritis & psoriatic arthritis
Comparative risk of incident and recurrent acute anterior uveitis across different biological agents in patients with ankylosing spondylitis
Authors' conclusion
Our data suggest preference for bDMARDs in the following order: adalimumab/golimumab > infliximab > secukinumab > etanercept (for incident AAU prevention) and adalimumab > golimumab/infliximab/secukinumab > etanercept (for recurrent AAU prevention).
Study context
- Population
- Patients with AS without previous history of acute anterior uveitis (AAU), national claims database, followed 2010–2021
- Participants
- 34,621 patients
- Exposure
- Different bDMARDs vs bDMARD non-exposure
- Outcome
- Incident and recurrent acute anterior uveitis (AAU)
Methodological detailsnationwide, national claims database, multivariable time-dependent Cox models, counting process (Anderson-Gill) models
- Nationwide
- National claims database
- Multivariable time-dependent Cox models
- Counting process (Anderson-Gill) models
Main finding
As reported in the abstract
Incident AAU
Adjusted hazard ratio (95% CI)
Adalimumabvs bDMARDs non-exposure
0.674(0.581–0.891)
Etanerceptvs bDMARDs non-exposure
1.760(1.540–2.012)
Golimumabvs bDMARDs non-exposure
0.771(0.620–0.959)
Infliximabvs bDMARDs non-exposure
0.891(0.741–1.071)
Secukinumabvs bDMARDs non-exposure
1.324(0.794–2.209)
Etanerceptvs Adalimumab
2.553(2.114–3.083)
Infliximabvs Adalimumab
1.303(1.039–1.634)
Secukinumabvs Adalimumab
2.173(1.273–3.710)
Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | |
|---|---|---|
| Recurrent AAUAdalimumabvs bDMARDs non-exposureCo-primary with incident AAU | 0.798 (0.659–0.968) | |
| Recurrent AAUEtanerceptvs bDMARDs non-exposureCo-primary with incident AAU | 1.416 (1.185–1.693) | |
| Recurrent AAUGolimumabvs bDMARDs non-exposureCo-primary with incident AAU | 0.874 (0.645–1.185) | |
| Recurrent AAUInfliximabvs bDMARDs non-exposureCo-primary with incident AAU | 0.926 (0.729–1.177) | |
| Recurrent AAUSecukinumabvs bDMARDs non-exposureCo-primary with incident AAU | 1.257 (0.670–2.359) | |
| Recurrent AAUEtanerceptvs AdalimumabCo-primary with incident AAU | 1.793 (1.403–2.292) | |
| 0.512Adjusted hazard ratio (log scale) |
Original publication
Comparative risk of incident and recurrent acute anterior uveitis across different biological agents in patients with ankylosing spondylitis. Rheumatology (Oxford). Published 18 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →